TI
XFOR icon

Trexquant Investment’s X4 Pharmaceuticals XFOR Stock Holding History

Trexquant Investment’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-554
Closed -$88K – 1669
2021
Q3 		$88K Sell
554
-289
-34% -$47.5K 0.01% 1061
2021
Q2 		$164K Buy
+843
New +$212K 0.01% 947

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Trexquant Investment's XFOR Position: Q4 2021 in Review

Trexquant Investment sold out of X4 Pharmaceuticals (XFOR) in Q4 2021, closing a stake of 554 shares — an estimated $88K sold.

Trexquant Investment first reported a position in XFOR in Q2 2021 and held it in 2 quarters. The position peaked at $164K in Q2 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2021.

  • Trexquant Investment reported no remaining X4 Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Trexquant Investment sold 554 X4 Pharmaceuticals shares in Q4 2021, an estimated $88K.
  • Trexquant Investment first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Trexquant Investment's X4 Pharmaceuticals position peaked at $164K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2021.

Based on Trexquant Investment's 13F filing for Q4 2021, filed 14 Feb 2022.